Allergan Announces Two Clinical Trials of Brazikumab for Crohn’s Disease and Ulcerative Colitis

Allergan Announces Two Clinical Trials of Brazikumab for Crohn’s Disease and Ulcerative Colitis
Allergan recently announced two new clinical trials to the test the efficacy of its investigational therapy, Brazikumab, for treatment of two forms of inflammatory bowel disease. The two clinical trials, INTREPID and EXPEDITION, will evaluate brazikumab therapy in Crohn’s disease and ulcerative colitis, respectively. Disease-specific biomarkers will be monitored to assess the treatment outcome. EXPEDITION is currently enrolling participants; more information can be found here. "If we are able to identify whether certain biomarkers can predict a response to treatment, we may be able to select the most appropriate therapy for patients earlier," Bruce E. Sands, MD, Dr. Burrill B. Crohn Professor of Medicine at Mount Sinai Hospital in New York, said in a press release. Brazikumab (also known as AMG-139; MEDI-2070) is an anti-inflammatory investigational drug that has the potential to curb inflammation by blocking the proinflammatory molecule interleukin-23. A high anti-inflammatory response of brazikumab in Crohn’s disease patients observed in a previously published Phase 2 study (NCT01714726
Subscribe or to access all post and page content.